SCHEMBL14636243

SCHEMBL14636243

O=C(OCc1ccccc1)N1CC(C2=C3C=NC=C[N+]3(Cl)C=N2)CCC1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
PREP P48147 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ACE2 Q9BYF1 2/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
CYP2C19 P33261 1/20 0.32
AGTR2 P50052 2/20 0.32
F2 P00734 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14639476 0.84 PDK1 (0.36) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL2323327 0.83 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL593237 0.82 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL15877465 0.79 F2 (0.36) SMN1; SMN2NPC1RAB9ACYP2C19F2
SCHEMBL2323407 0.79 SIGMAR1 (0.42) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL15878780 0.79 PREP (0.39) PREP
SCHEMBL2327301 0.71 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL2324493 0.71 MEN1 (0.44) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL14637752 0.71 ALDH1A1 (0.39)
SCHEMBL23159867 0.71 PDK1 (0.49) PDK1PDK2PDK3PDK4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2734529-B1 BTK INHIBITORS MERCK SHARP & DOHME (US) 2018-09-05 EP disclosed
US-9718828-B2 BTK Inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-01 US disclosed
US-20170008899-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 US disclosed
EP-2734529-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-28 EP disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008899-A1 BTK INHIBITORS BTK, SYK, ABL1 PDK1 714/4885PDK2 1188/4885PDK3 1869/4885
US-20140221333-A1 BTK INHIBITORS BTK, SYK, ABL1 PDK1 675/4885PDK2 1180/4885PDK3 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.